Literature DB >> 16794889

[Attitudes towards predictive genetic testing for Alzheimer's disease].

F Illes1, T Bernhardt, K Prell, C Rietz, G Rudinger, L Frölich, W Maier, M Rietschel.   

Abstract

Most neuropsychiatric disorders have a complex aetiology. Discovery of the underlying genetics will provide insights into the disorders and allow the subsequent development of therapeutic interventions based upon an understanding of causality. The first vulnerability genes in Alzheimer's disease (AD) have been identified. The contribution of each vulnerability gene to the disorder is limited and does not enable prediction of course and onset in individual cases, only modification of the a priori risk. However, people may wish to be informed about this modification. Professionals have not favoured this form of predictive testing due to an awareness of its limitations and its potential for harm. However, little is known about public attitudes and understanding of such genetic testing in neuropsychiatric disorders. The aim of our study was to assess the attitudes of the general population and to explore the influence on these attitudes of knowledge about the illness and the understanding of risk information. In our study, a representative sample of the German general population (n=2001), relatives of patients with Alzheimer's disease (n=101) and physicians (n=43) were interviewed about their attitudes towards genetic tests for Alzheimer's disease and their perception and interpretation of risk information. To assess the influence of genetic counselling on these factors, 234 people were questioned before, and four weeks after, they were provided with detailed relevant information. Our results indicate that a substantial proportion of the German population (57%) is in favour of psychiatric genetic testing for AD in general. Even when the explanatory power of a genetic test is limited, a substantial proportion of the population (47%) expressed an interest in genetic testing. Counselling slightly decreased the interest in having a genetic test for oneself (from 47% to 38%). Physicians were more hesitant than both relatives and the general population concerning predictive genetic testing. Only a minority (11%) favoured prenatal genetic testing. Our results also show that both knowledge about AD and the capacity to interpret risk estimates are limited. While physicians' estimation of their personal risk for developing AD approximated to the actual average risk for the population, people in the general population and the relatives of AD patients tended to overestimate their personal risk. However, most of the general population still perceived this risk as average or low. While most physicians could correctly interpret information regarding the probability of risk, only one third of AD patients' relatives or members of the general population could. As the decision of an individual to undergo predictive testing relies mainly on his understanding of risk, the ability to correctly interpret risk information will be of crucial importance in the future. From a medical perspective, the prevailing approach of professional associations to genetic testing appears reasonable and therefore should not be changed at present.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16794889     DOI: 10.1007/s00391-006-0377-3

Source DB:  PubMed          Journal:  Z Gerontol Geriatr        ISSN: 0948-6704            Impact factor:   1.281


  6 in total

Review 1.  Genetic risk of Alzheimer's disease: advising relatives.

Authors:  M B Liddell; S Lovestone; M J Owen
Journal:  Br J Psychiatry       Date:  2001-01       Impact factor: 9.319

Review 2.  Genetic susceptibility factors for Alzheimer's disease.

Authors:  F Richard; P Amouyel
Journal:  Eur J Pharmacol       Date:  2001-01-19       Impact factor: 4.432

Review 3.  The genetic epidemiology of neurodegenerative disease.

Authors:  Lars Bertram; Rudolph E Tanzi
Journal:  J Clin Invest       Date:  2005-06       Impact factor: 14.808

Review 4.  [Dementia in advanced age: estimating incidence and health care costs].

Authors:  H Bickel
Journal:  Z Gerontol Geriatr       Date:  2001-04       Impact factor: 1.281

Review 5.  Understanding probabilistic risk in predisposition genetic testing for Alzheimer disease.

Authors:  B A Koenig; H L Silverberg
Journal:  Genet Test       Date:  1999

6.  Rates and risk factors for dementia and Alzheimer's disease: results from EURODEM pooled analyses. EURODEM Incidence Research Group and Work Groups. European Studies of Dementia.

Authors:  L J Launer; K Andersen; M E Dewey; L Letenneur; A Ott; L A Amaducci; C Brayne; J R Copeland; J F Dartigues; P Kragh-Sorensen; A Lobo; J M Martinez-Lage; T Stijnen; A Hofman
Journal:  Neurology       Date:  1999-01-01       Impact factor: 9.910

  6 in total
  3 in total

1.  Attitudes towards cannabis use and genetic testing for schizophrenia.

Authors:  Jason Schiffman; Ryan E Lawrence; Caroline Demro; Paul S Appelbaum; Lisa B Dixon
Journal:  Early Interv Psychiatry       Date:  2014-06-23       Impact factor: 2.732

2.  Attitudes toward the right to autonomous decision-making in psychiatric genetic testing: Controversial and context-dependent.

Authors:  Jana Strohmaier; Stephanie H Witt; Josef Frank; Noemi Lemme; Laura Flatau; Fabian Streit; Jerome C Foo; Markus Reitt; Dan Rujescu; Thomas G Schulze; Dirk Lanzerath; Franciska Illes; Franziska Degenhardt; Marcella Rietschel
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2019-03-26       Impact factor: 3.568

3.  Attitudes of the German general population toward early diagnosis of dementia--results of a representative telephone survey.

Authors:  Tobias Luck; Melanie Luppa; Jennifer Sieber; Georg Schomerus; Perla Werner; Hans-Helmut König; Steffi G Riedel-Heller
Journal:  PLoS One       Date:  2012-11-27       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.